Matta M, Saglietto A, De Salvo P, Bissolino A, Ballatore A, Anselmino M
Division of Cardiology, Sant'Andrea Hospital, Vercelli, Italy.
Division of Cardiology, Department of Medical Sciences, "Città della Salute e della Scienza" Hospital, University of Turin, Corso Bramante 88, 10126, Turin, Italy.
Herz. 2019 May;44(3):218-222. doi: 10.1007/s00059-019-4794-7.
Atrial fibrillation (AF) is the most commonly sustained arrhythmia, and patients with diabetes mellitus (DM) exhibit an increased incidence of AF. Besides DM, heart failure (HF) shares pathophysiological links with AF, mainly related to the pathological remodeling of hearts affected by structural disease. As in a vicious circle, AF may contribute to HF worsening and increased mortality in patients with structural heart diseases, and the outcome may be further impaired when concomitant DM is present. Although no data directly referring to DM patients with HF are available, indirect information can be drawn from large studies on patients with HF and AF. The present review discusses the outcome of AF ablation in patients with DM and HF, focusing on safety, efficacy, and most particularly on hard endpoints such as mortality and thromboembolic event incidence.
心房颤动（AF）是最常见的持续性心律失常，糖尿病（DM）患者发生AF的几率更高。除糖尿病外，心力衰竭（HF）与AF存在病理生理联系，主要与受结构性疾病影响的心脏病理重塑有关。如同恶性循环一般，AF可能会导致结构性心脏病患者的HF恶化及死亡率增加，而当合并糖尿病时，病情可能会进一步恶化。虽然目前尚无直接针对糖尿病合并HF患者的数据，但可从有关HF和AF患者的大型研究中获取间接信息。本综述讨论了糖尿病合并HF患者AF消融的结果，重点关注安全性、有效性，尤其是死亡率和血栓栓塞事件发生率等硬性终点。
